New understanding about the pathophysiology of the condition, along with new clinical trial endpoints for approval, have ...

No therapies currently exist that can halt the progression of chronic kidney disease in children or restore the ability of kidney cells to filter blood. Recently, researchers at the GOFARR Laboratory ...

Sodium reduction and appropriate protein intake are central nutrition strategies for slowing kidney stress and supporting ...

Detailed price information for Cspc Pharm Group Ltd Ord (CHJTF) from The Globe and Mail including charting and trades.

Alternative pathway blockade via factor B inhibition limits C3 cleavage, amplification loop activity, and downstream membrane ...

Half of patients treated for IgA nephropathy relapse within 10 years and experience substantial kidney function decline. The proteinuria target is lower than most expect. Relapse is common among ...

The final analysis showed treatment with sparsentan reduced the rate of decline in kidney function vs irbesartan. The Food and Drug Administration (FDA) has granted full approval to Filspari ® ...

To claim CE credit for this activity, please visit https://www.pharmacytimes.org/courses/preventing-progression-in-iga-nephropathy-a-managed-care-focus-on-emerging ...

Effective therapy of post-transplant membranous nephropathy may improve outcomes. Membranous nephropathy (MN) recurs after kidney transplantation in nearly a third of patients with a history of MN but ...

Between 20 and 50 percent of individuals with IgA nephropathy will experience kidney failure within two decades of diagnosis, though the timeline varies significantly from person to person. Regular ...

Diabetic nephropathy is a common complication associated with diabetes that affects a person’s kidneys. Several medications may help slow the progression of kidney damage. Early treatment can prevent ...